Zobrazeno 1 - 10
of 32
pro vyhledávání: '"S R, Burzynski"'
Autor:
J. L. Clarke, M. M. Ennis, K. R. Lamborn, M. D. Prados, V. K. Puduvalli, M. Penas-Prado, M. R. Gilbert, M. D. Groves, K. R. Hess, V. A. Levin, J. de Groot, H. Colman, C. A. Conrad, M. E. Loghin, K. Hunter, W. K. Yung, C. Chen, D. Damek, A. Liu, L. E. Gaspar, A. Waziri, K. Lillehei, B. Kavanagh, J. L. Finlay, K. Haley, G. Dhall, S. Gardner, J. Allen, A. Cornelius, R. Olshefski, J. Garvin, K. Pradhan, M. Etzl, S. Goldman, M. Atlas, S. Thompson, A. Hirt, J. Hukin, M. Comito, S. Bertolone, J. Torkildson, M. Joyce, C. Moertel, J. Letterio, G. Kennedy, A. Walter, L. Ji, R. Sposto, K. Dorris, L. Wagner, T. Hummel, R. Drissi, L. Miles, J. Leach, L. Chow, R. Turner, M. N. Gragert, D. Pruitt, M. Sutton, J. Breneman, K. Crone, M. Fouladi, B. B. Friday, J. Buckner, S. K. Anderson, C. Giannini, J. Kugler, M. Mazurczac, P. Flynn, H. Gross, E. Pajon, K. Jaeckle, E. Galanis, M. A. Badruddoja, M. A. Pazzi, B. Stea, P. Lefferts, N. Contreras, M. Bishop, J. Seeger, R. Carmody, N. Rance, M. Marsella, K. Schroeder, A. Sanan, L. J. Swinnen, C. Rankin, E. J. Rushing, L. F. Hutchins, D. M. Damek, G. R. Barger, A. D. Norden, G. Lesser, S. N. Hammond, J. Drappatz, C. E. Fadul, T. T. Batchelor, E. C. Quant, R. Beroukhim, A. Ciampa, L. Doherty, D. LaFrankie, S. Ruland, C. Bochacki, P. Phan, E. Faroh, B. McNamara, K. David, M. R. Rosenfeld, P. Y. Wen, S. Phuphanich, D. Reardon, E. T. Wong, S. R. Plotkin, A. Mintz, J. J. Raizer, T. J. Kaley, K. H. Smith, M. C. Chamberlain, C. Graham, M. Mrugala, S. Johnston, T. N. Kreisl, P. Smith, F. Iwamoto, J. Sul, J. A. Butman, H. A. Fine, M. Westphal, O. Heese, M. Warmuth-Metz, T. Pietsch, U. Schlegel, J.-C. Tonn, J. Schramm, G. Schackert, A. Melms, H. M. Mehdorn, V. Seifert, K. Geletneky, D. Reuter, F. Bach, M. Khasraw, L. E. Abrey, A. B. Lassman, A. Hormigo, C. Nolan, I. T. Gavrilovic, I. K. Mellinghoff, A. S. Reiner, L. DeAngelis, A. M. Omuro, S. R. Burzynski, R. A. Weaver, T. J. Janicki, G. S. Burzynski, B. Szymkowski, S. S. Acelar, L. L. Mechtler, P. C. O'Connor, H.-A. Kroon, T. Vora, P. Kurkure, B. Arora, T. Gupta, V. Dhamankar, S. Banavali, A. Moiyadi, S. Epari, N. Merchant, R. Jalali, S. Moller, K. Grunnet, S. Hansen, H. Schultz, M. Holmberg, M. M. Sorensen, H. S. Poulsen, U. Lassen, D. A. Reardon, J. J. Vredenburgh, A. Desjardins, D. E. Janney, K. Peters, J. Sampson, S. Gururangan, H. S. Friedman, S. Jeyapalan, M. Constantinou, D. Evans, H. Elinzano, B. O'Connor, M. Y. Puthawala, M. Goldman, A. Oyelese, D. Cielo, T. Dipetrillo, H. Safran, M. Anan, M. Seyed Sadr, J. Alshami, C. Sabau, E. Seyed Sadr, V. Siu, M.-C. Guiot, A. Samani, R. Del Maestro, U. Bogdahn, G. Stockhammer, A. K. Mahapatra, N. K. Venkataramana, V. E. Oliushine, V. E. Parfenov, I. E. Poverennova, P. Hau, P. Jachimczak, H. Heinrichs, K.-H. Schlingensiepen, S. Shibui, T. Kayama, T. Wakabayashi, R. Nishikawa, M. de Groot, E. Aronica, C. J. Vecht, S. T. Toering, J. J. Heimans, J. C. Reijneveld, T. Batchelor, P. Mulholland, B. Neyns, L. B. Nabors, M. Campone, A. Wick, W. Mason, T. Mikkelsen, L. S. Ashby, J. F. DeGroot, H. R. Gattamaneni, L. M. Cher, M. A. Rosenthal, F. Payer, J. Xu, Q. Liu, M. van den Bent, B. Nabors, K. Fink, M. Chan, J. Trusheim, S. Raval, C. Hicking, J. Henslee-Downey, M. Picard, D. Schiff, S. Karimi, L. M. DeAngelis, C. P. Nolan, A. Omuro, I. Gavrilovic, A. Norden, B. W. Purow, F. S. Lieberman, S. Hariharan, J. G. Perez-Larraya, J. Honnorat, O. Chinot, I. Catry-Thomas, L. Taillandier, J. S. Guillamo, C. Campello, A. Monjour, M. L. Tanguy, J. Y. Delattre, D. N. Franz, D. A. Krueger, M. M. Care, K. Holland-Bouley, K. Agricola, C. Tudor, P. Mangeshkar, A. W. Byars, T. Sahmoud, M. Alonso-Basanta, R. A. Lustig, J. F. Dorsey, R. K. Lai, L. D. Recht, N. Paleologos, M. Groves, S. Meech, T. Davis, D. Pavlov, M. A. Marshall, M. Slot, S. M. Peerdeman, P. D. Beauchesne, G. Faure, G. Noel, T. Schmitt, C. Kerr, E. Jadaud, L. Martin, C. Carnin, K. B. Peters, J. E. Herndon, J. P. Kirkpatrick, L. Nayak, K. S. Panageas, L. M. Deangelis
Publikováno v:
Neuro-Oncology. 12:iv69-iv78
Publikováno v:
Drugs under experimental and clinical research. 21(4)
A new therapeutic strategy for the treatment of Parkinson's disease (PD) is based on providing trophic support for degenerating dopaminergic (DA) neurons. It can be accomplished by administration of neurotrophic factors, or inducing astrocytes to dif
Publikováno v:
Drugs under experimental and clinical research. 20(4)
Antineoplastons are naturally occurring cytodifferentiating agents. Chemically, antineoplastons are medium and small sized peptides, amino acid derivatives and organic acids which exist in blood, tissues and urine. In clinical trials in advanced canc
Publikováno v:
Drugs under experimental and clinical research. 16(7)
Successful treatment of advanced cancer of the prostate which no longer responds to hormonal manipulation continues to be a difficult task. The present study describes the results of treatment of the first fourteen patients in Phase II clinical trial
Autor:
S. R. Burzynski
Publikováno v:
Integrative Cancer Therapies. 3:200-200
Autor:
M C, Liau, S R, Burzynski
Publikováno v:
Drugs under experimental and clinical research. 12
MC2 is a ternary enzyme complex consisting of MAT, methyltransferase and SAHH. Three isozymes of SAHH have been identified from rat and mouse livers based on different kinetic properties. The Km values are 0.35 +/- 0.05 microM, 1.63 +/- 0.38 microM a
Autor:
M, Khalid, S R, Burzynski
Publikováno v:
Drugs under experimental and clinical research. 13
Previous studies carried out in the authors' Institute revealed that one of the active metabolites of Antineoplaston A10 is phenylacetylisoglutamine. The objective of this study is screening of N,N'-disubstituted L-isoglutamine derivatives for select
Publikováno v:
Drugs under experimental and clinical research. 12
Antineoplaston AS2-1 and Antineoplaston AS2-5 are degradation products of Antineoplaston A10. The initial hydrolysis of Antineoplaston A10 (3-phenylacetylamine-2, 6-piperidinedione) yields phenylacetylglutamine and phenylacetylisoglutamine. When hydr
Publikováno v:
Drugs under experimental and clinical research. 12
Antineoplaston A10 (3-phenylacetylamino-2,6-piperidinedione), a peptide analogue originally isolated from human urine and serum, appears to have antineoplastic activity. In view of the close resemblance of the structure of A10 to that of DNA intercal
Autor:
S R, Burzynski, E, Kubove
Publikováno v:
Drugs under experimental and clinical research. 12
Antineoplaston A10 injections were administered to 18 patients diagnosed with 19 types of neoplastic disease. The patients' diagnoses included: adenocarcinoma of the rectum and colon, Stage IV (8 cases); adenocarcinoma of the pancreas (4 cases); aden